<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087513</url>
  </required_header>
  <id_info>
    <org_study_id>16-5926-B</org_study_id>
    <nct_id>NCT03087513</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo</brief_title>
  <official_title>Effect of Reversal of Neuromuscular Blockade on the Amplitude of Motor Evoked Potentials: A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraoperative monitoring of the motor evoked potentials has been shown to be both a
      sensitive and specific indicator for detecting intraoperative neurological injuries during
      spine surgery.(Fehlings, Brodke et al. 2010) It is utilized whenever there is risk for injury
      of nerve roots or the spinal cord during the procedure.

      Anesthetic agents, especially the inhaled volatile anesthetics and muscle relaxants, are
      con-founders for motor evoked potential monitoring as they have deleterious effects on the
      amplitude of motor evoked potentials.(Sekimoto, Nishikawa et al. 2006) Hence, total
      intravenous anesthesia with no intraoperative muscle relaxants, are the standard anesthetic
      technique for these surgeries.

      Muscle relaxants are usually required during the induction of anesthesia and endotracheal
      intubation of larynx. Current practice is to wait for the resolution of residual
      neuromuscular blockade before the motor evoked potential recordings (MEP) are initiated and
      this makes it difficult to assess if there was any neurological injury associated with
      positioning of the patient. A previous case series has shown that reversal of muscle relaxant
      can improve the amplitude of MEPs.(Batistaki, Papadopoulos et al. 2012) The aim of this study
      is to perform a randomized controlled trial to study the changes in motor evoked potential
      amplitudes comparing sugammadex and placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Motor evoked potential monitoring is a well-established and safe intervention to assist in
      prevention of intraoperative injury during spine surgery.(Schwartz, Sestokas et al. 2011)
      Patients with cervical myelopathy often present with neurological deficits and recording of
      the motor evoked potentials are often challenging in these patients. In addition, anesthetic
      agents especially muscle relaxants can abolish the motor response making it difficult to know
      when the baseline MEP can be recorded.

      The usual anesthetic practice for patients undergoing posterior cervical spine surgery is to
      administer muscle relaxation to aid intubation at the start of the case . The neuromuscular
      blockade is then allowed to wear off and the neurophysiologist will attempt to record their
      baseline motor evoked potentials during or just prior to surgical exposure.

      The issues with this current technique are;

        1. Patients cannot be monitored for neurological changes during their transfer into the
           prone position

        2. There is likely residual neuromuscular blockade decreasing the amplitude of motor evoked
           potentials.

      Investigators plan to perform a randomized controlled cross-over trial comparing the change
      in MEP amplitudes with administration of sugammadex or placebo. This will be performed on at
      risk patients (e.g. cervical myelopathy) undergoing posterior cervical spine surgery where
      MEPs can be more difficult to attain but of higher utility.

      The purpose of this study is to determine if reversal of residual neuromuscular blockade with
      Sugammadex can increase the amplitude of the motor evoked potentials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized controlled crossover trial comparing the change in MEP amplitudes with administration of sugammadex or placebo.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a randomized blinded study where the administering anesthetist, surgeon and neurophysiologists will be blinded to the intervention.
Further, a blinded research assistant will perform assessment, data collection, and analysis of neurophysiology data attained.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes Motor Evoked Potentials (MEPs) Amplitude at 3 Minutes</measure>
    <time_frame>Baseline and 3 minutes after the study intervention</time_frame>
    <description>Changes in the amplitude of the Motor Evoked Potentials from the baseline in the first dorsal interosseous muscle at 3 minutes in sugammadex group compared to placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MEPs Amplitude Changes in Both Sugammadex and Placebo Groups</measure>
    <time_frame>Baseline to 6 minutes</time_frame>
    <description>Changes in the amplitude of the MEPs from the baseline in the first dorsal interosseous muscle at 6 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEPs Amplitude Changes From Baseline at 9 Minutes</measure>
    <time_frame>Baseline to 9 minutes</time_frame>
    <description>Comparison of changes in MEP amplitudes from baseline at 9 minutes between sugammadex and placebo groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Movement</measure>
    <time_frame>From 0 to 15 minutes</time_frame>
    <description>Number of patients moved and observed by the surgeon. From the study intervention to the surgeon observed patient movements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Grading of Relaxation of the Surgical Field</measure>
    <time_frame>approximatelt 1 hour - 30 min during surgical exposure and 30 minutes during closure</time_frame>
    <description>Surgical grading of relaxation of the surgical field as per the Likert-4 point surgical grading of surgical field.
During surgical exposure and closure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Posterior Cervical Decompression and Fusion</condition>
  <arm_group>
    <arm_group_label>Initial Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study participants will receive either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study participants will receive the study medication that was not given in the initial arm (either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline) .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex Injection [Bridion]</intervention_name>
    <description>The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.</description>
    <arm_group_label>Crossover Arm</arm_group_label>
    <arm_group_label>Initial Arm</arm_group_label>
    <other_name>Sugammadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.</description>
    <arm_group_label>Crossover Arm</arm_group_label>
    <arm_group_label>Initial Arm</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients aged 18-80 years with American Society of Anesthesiologist (ASA)
             classification I-III undergoing cervical spine surgery in the prone position with
             intraoperative motor evoked potential monitoring.

          -  Operation time greater than 3 hours

        Exclusion Criteria:

          -  Allergy to propofol or documented egg allergy

          -  Known allergy to sugammadex

          -  Severe renal dysfunction (EGFR&lt;30)

          -  British Research Medical Council (BRMC) motor grading &lt;3 in any peripheral muscle
             group preoperatively. This is inability to move the muscle group against gravity.

          -  Surgical requirement of strict muscle relaxation for surgical exposure

          -  Lack of informed consent

          -  Pregnancy

          -  Loss of MEP signals during washout period (or intraoperative spinal cord injury
             resulting in irreversible loss of MEP)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lashmi Venkatraghavan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TWH/UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <results_first_submitted>May 1, 2020</results_first_submitted>
  <results_first_submitted_qc>May 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2020</results_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Lashmi Venkatraghavan</investigator_full_name>
    <investigator_title>Associate Professor, Department of Anesthesia, Toronto Western Hospital, Toronto, Canada</investigator_title>
  </responsible_party>
  <keyword>Motor Evoked Potentials, Spine surgery, Muscle relaxants</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03087513/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between February 2018 and April 2019, 73 posterior cervical spine patients screened from the preoperative assessment clinic of Toronto Western Hospital to identify eligible patients.
First participant was enrolled on March 2018 and the last participant was enrolled on April 2019.</recruitment_details>
      <pre_assignment_details>40 participants received 10ml syringe containing Sugammadex (2mg/kg) in the first phase, followed by Placebo 10 ml in the second phase or 10ml syringe containing Placebo in the first phase, followed by 10 ml of Sugammadex (2mg/kg) in the second phase.
Time interval of approximately 3 hours between initial and crossover arm. 2 Patients withdrawn</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Initial Arm and Crossover Arm</title>
          <description>The study participants will receive either 10ml syringe containing Sugammadex (2mg/kg) or 10 ml Placebo 10 ml in the initial arm and in the crossover arm they will recieve the other drug ( sugammadex or Placebo) Washout period is 3 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention After 3 hr Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Equipment malfunction</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Intervention</title>
          <description>Initial Arm The study participants will receive10ml syringe containing Sugammadex (2mg/kg) in the first phase, followed by 10 ml of Placebo in the second phase.
Cross-over Arm The study participants will receive10ml syringe containing Placebo in the first phase, followed by 10 ml of Sugammadex (2mg/kg) in the second phase.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Motor Evoked Potential amplitudes in both baseline and cross-over arms</title>
          <units>micro volts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Left FDI Sugammedex Group</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="544.4" lower_limit="165.8" upper_limit="1300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left FDI Placebo Group</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="377.1" lower_limit="107.2" upper_limit="1650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right FDI Sugammedex Group</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="439.6" lower_limit="101" upper_limit="1900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right FDI Placebo Group</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="418.7" lower_limit="83.7" upper_limit="1425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes Motor Evoked Potentials (MEPs) Amplitude at 3 Minutes</title>
        <description>Changes in the amplitude of the Motor Evoked Potentials from the baseline in the first dorsal interosseous muscle at 3 minutes in sugammadex group compared to placebo group</description>
        <time_frame>Baseline and 3 minutes after the study intervention</time_frame>
        <population>Data are presented as Median (IQR). MEP- Motor evoked potential, µV-microvolt, min-minute, 1Q- First quartile, 3Q-third quartile, FDI- first dorsal interosseous</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex</title>
            <description>The study participants will receive a 10 ml syringe containing sugammadex (2mg/kg) in the first phase, followed by placebo 10 ml (0.9% normal saline) in the second phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The study participants will receive a 10ml syringe containing placebo (0.9% normal saline) in the first phase, followed by sugammadex 10 ml (2mg/kg) in the second phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Motor Evoked Potentials (MEPs) Amplitude at 3 Minutes</title>
          <description>Changes in the amplitude of the Motor Evoked Potentials from the baseline in the first dorsal interosseous muscle at 3 minutes in sugammadex group compared to placebo group</description>
          <population>Data are presented as Median (IQR). MEP- Motor evoked potential, µV-microvolt, min-minute, 1Q- First quartile, 3Q-third quartile, FDI- first dorsal interosseous</population>
          <units>micro volts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left FDI amplitude changes from baseline at 3 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="652.9" lower_limit="142" upper_limit="1650"/>
                    <measurement group_id="O2" value="20.6" lower_limit="-183.5" upper_limit="297.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right FDI amplitude changes from baseline at 3 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2153.4" lower_limit="1400" upper_limit="4536.8"/>
                    <measurement group_id="O2" value="55" lower_limit="-65.2" upper_limit="480.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>In total, 40 patients were randomised for the study. Data from 2 patients were excluded as the crossover arm could not be completed due to intraoperative MEP change (n=1) and the equipment malfunction (n=1). The data distributions were tested for normality with the Kolmogorov–Smirnov test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>In all cases of motor evoked potential changes, a P-value of 0.05 was considered significant.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>As the amplitude values were non-normally distributed, the Mann-Whitney U test was performed to compare the two groups.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEPs Amplitude Changes in Both Sugammadex and Placebo Groups</title>
        <description>Changes in the amplitude of the MEPs from the baseline in the first dorsal interosseous muscle at 6 minutes</description>
        <time_frame>Baseline to 6 minutes</time_frame>
        <population>Data are presented as Median (IQR). MEP- Motor evoked potential, µV-microvolt, min-minute, 1Q- First quartile, 3Q-third quartile, FDI- first dorsal interosseous</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex Group</title>
            <description>The study participants will receive a 10ml syringe containing sugammadex (2mg/kg) in the first phase, followed by placebo (10 ml of 0.9% normal saline) in the second phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>The study participants will receive a 10 ml syringe containing placebo (0.9% normal saline) in the first phase, followed by sugammadex 10 ml (2mg/kg) in the second phase.</description>
          </group>
        </group_list>
        <measure>
          <title>MEPs Amplitude Changes in Both Sugammadex and Placebo Groups</title>
          <description>Changes in the amplitude of the MEPs from the baseline in the first dorsal interosseous muscle at 6 minutes</description>
          <population>Data are presented as Median (IQR). MEP- Motor evoked potential, µV-microvolt, min-minute, 1Q- First quartile, 3Q-third quartile, FDI- first dorsal interosseous</population>
          <units>micro volts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left FDI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="646.4" lower_limit="253.1" upper_limit="1580.9"/>
                    <measurement group_id="O2" value="84.3" lower_limit="-178.6" upper_limit="679.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right FDI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1609.3" lower_limit="632.4" upper_limit="5535.7"/>
                    <measurement group_id="O2" value="201.9" lower_limit="-0.525" upper_limit="760.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEPs Amplitude Changes From Baseline at 9 Minutes</title>
        <description>Comparison of changes in MEP amplitudes from baseline at 9 minutes between sugammadex and placebo groups</description>
        <time_frame>Baseline to 9 minutes</time_frame>
        <population>Data are presented as Median (IQR). MEP- Motor evoked potential, µV-microvolt, min-minute, 1Q- First quartile, 3Q-third quartile, FDI- first dorsal interosseous</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammedex Group</title>
            <description>The study participants will receive a 10ml syringe containing sugammadex (2mg/kg) in the first phase, followed by placebo (10 ml 0.9% normal saline) in the second phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>The study participants will receive a 10 ml syringe containing placebo (0.9% normal saline) in the first phase, followed by sugammadex 10 ml (2mg/kg) in the second phase.</description>
          </group>
        </group_list>
        <measure>
          <title>MEPs Amplitude Changes From Baseline at 9 Minutes</title>
          <description>Comparison of changes in MEP amplitudes from baseline at 9 minutes between sugammadex and placebo groups</description>
          <population>Data are presented as Median (IQR). MEP- Motor evoked potential, µV-microvolt, min-minute, 1Q- First quartile, 3Q-third quartile, FDI- first dorsal interosseous</population>
          <units>micro volts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left FDI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="894.9" lower_limit="234.1" upper_limit="2261.2"/>
                    <measurement group_id="O2" value="105.5" lower_limit="-115.2" upper_limit="775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right FDI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1256.3" lower_limit="308.9" upper_limit="2533.1"/>
                    <measurement group_id="O2" value="337.2" lower_limit="-17.5" upper_limit="2215.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Movement</title>
        <description>Number of patients moved and observed by the surgeon. From the study intervention to the surgeon observed patient movements</description>
        <time_frame>From 0 to 15 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex Group</title>
            <description>The study participants will receive a 10ml syringe containing sugammadex (2mg/kg) in the first phase, followed by placebo (10 ml 0.9% normal saline) in the second phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>The study participants will receive a 10ml syringe containing placebo (0.9% normal saline) in the first phase, followed by sugammadex 10 ml (2mg/kg) in the second phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Movement</title>
          <description>Number of patients moved and observed by the surgeon. From the study intervention to the surgeon observed patient movements</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Grading of Relaxation of the Surgical Field</title>
        <description>Surgical grading of relaxation of the surgical field as per the Likert-4 point surgical grading of surgical field.
During surgical exposure and closure.</description>
        <time_frame>approximatelt 1 hour - 30 min during surgical exposure and 30 minutes during closure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex</title>
            <description>The study participants will receive a 10ml syringe containing sugammadex (2mg/kg) in the first phase, followed by placebo 10 ml in the second phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The study participants will receive a 10ml syringe containing placebo in the first phase, followed by sugammadex 10 ml (2mg/kg) in the second phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Grading of Relaxation of the Surgical Field</title>
          <description>Surgical grading of relaxation of the surgical field as per the Likert-4 point surgical grading of surgical field.
During surgical exposure and closure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Good or optimal condition</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Acceptable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the study intervention to the end of surgery, approximately 3 hours</time_frame>
      <desc>All adverse events occurring during the study intervention period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sugammadex Group</title>
          <description>The study participants will receive a 10ml syringe containing sugammadex (2mg/kg) in the first phase, followed by placebo (10 ml 0.9% normal saline) in the second phase.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>The study participants will receive a 10ml syringe containing placebo (0.9% normal saline) in the first phase, followed by sugammadex 10 ml (2mg/kg) in the second phase.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Coordinator</name_or_title>
      <organization>Toronto Western Hospital/University Health Network</organization>
      <phone>416-603-5800 ext 6237</phone>
      <email>emad.alazazi@uhnresearch.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

